Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA to Revise Its FY2004-2008 Business Plan in March
March 5, 2007
- Otsuka to Gear Up Promotion of Abilify
March 5, 2007
- REGULATORY NEWS IN BRIEF
March 5, 2007
- Mochida Joins Novartis to Promote Diovan
March 5, 2007
- Prefectures Generally Unenthusiastic about Promoting Use of Generics
March 5, 2007
- Vesicare Leads Market for Pollakisuria, Urinary Incontinence
March 5, 2007
- Ohara Pharm. Aims for Sales of \10 Bil. in FY2009
March 5, 2007
- Approval of Western Herbs as OTC Drugs Becoming Reality: JSMI
March 5, 2007
- SELF-MEDICATION NEWS IN BRIEF
March 5, 2007
- OPINION／Global Thinkers Wanted in a World of Change
March 5, 2007
- Japan's Total Healthcare Expenditure Is One of the Lowest among OECD Member Countries: JMA
March 5, 2007
- IT Grand Design Drafted by Korosho
March 5, 2007
- BUSINESS NEWS IN BRIEF
March 5, 2007
- More Radiologists, Radiotherapy Equipment Specialists Needed: Prof. Nakagawa
March 5, 2007
- Kowa, Kowa Pharmaceuticals to Integrate R&D, Production Functions
March 5, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 5, 2007
- PotelligentTM Technology Licensed to 8 Companies: BioWa
March 5, 2007
- SEMINAR
March 5, 2007
- Adiponectin, an Important Etiological Factor for Diabetes: Prof. Kadowaki
March 5, 2007
- TOPICS 2 articles
March 5, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…